Latest news with #Yuwell
Cision Canada
6 days ago
- Business
- Cision Canada
Yuwell PRIMEDIC Global Partners Conference Held in Germany - Signs Strategic Agreement with Safe Life to Expand Global First-Aid Market
STUTTGART, Germany, June 4, 2025 /CNW/ -- Yuwell PRIMEDIC successfully held its 2025 Global Partners Conference in Stuttgart, Germany, bringing together leadership and international distributors. The event spotlighted an expanded strategic alliance with Safe Life Group, embracing "The Next Wave" in first-aid solutions globally. Setting New Benchmarks in Emergency Solutions Yuwell Chairman, Mr. Alex WU, highlighted PRIMEDIC 's 52-year mission of "Saves life. Everywhere." He emphasized Yuwell 's commitment to further invest in PRIMEDIC to advice its position as a global leader in first-aid solutions and protect more lives worldwide. The conference also showcased a portfolio of first-aid products designed for public, EMS & clinical, and home use - jointly developed and manufactured in China and Germany. Emphasized products HeartSave myPAD, which is portable and handy size The HeartSave Y/YA series, which features both of blood oxygen and blood pressure monitoring These smart devices enable remote emergency assistance and one-touch alerts, delivering efficient solutions for complex scenarios. All products are EU MDR-certified, paving the way for further expansion across the European market. PRIMEDIC Global CEO, Dr. Jack JING announced plans to increase investment in AI-powered emergency response and remote medical connectivity. PRIMEDIC will launch over 10 strategic products to enhance integrated emergency solutions spanning EMS to clinical care, creating end-to-end health solutions from prevention through emergency response to recovery. Strengthening Global Reach Through Strategic Partnership with Safe Life While advancing product innovation, PRIMEDIC is also accelerating its global expansion. Financial reports show its emergency solutions segment generated ¥239 million (≈$33M USD) in 2024 revenue, a 34.05% year-on-year—driven by localized overseas operations and global supply chain partnerships. At the conference, PRIMEDIC signed a letter of intent with Safe Life Group. This expanded partnership builds on a 15-year relationship, combining shared values, complementary strengths, and integrated resources to accelerate PRIMEDIC 's presence across Europe and the United States while raising public awareness for emergency preparedness and response. As emergency scenarios diversify and IoT technology advances, the AED market is rapidly evolving toward smart, accessible solutions. PRIMEDIC will leverage its technical expertise and strategic vision to accelerate product innovations and international certifications, promoting global growth and delivering next-level emergency care worldwide.
Yahoo
6 days ago
- Business
- Yahoo
Yuwell PRIMEDIC Global Partners Conference Held in Germany - Signs Strategic Agreement with Safe Life to Expand Global First-Aid Market
STUTTGART, Germany, June 4, 2025 /CNW/ -- Yuwell PRIMEDIC successfully held its 2025 Global Partners Conference in Stuttgart, Germany, bringing together leadership and international distributors. The event spotlighted an expanded strategic alliance with Safe Life Group, embracing "The Next Wave" in first-aid solutions globally. Setting New Benchmarks in Emergency Solutions Yuwell Chairman, Mr. Alex WU, highlighted PRIMEDIC's 52-year mission of "Saves life. Everywhere." He emphasized Yuwell's commitment to further invest in PRIMEDIC to advice its position as a global leader in first-aid solutions and protect more lives worldwide. The conference also showcased a portfolio of first-aid products designed for public, EMS & clinical, and home use - jointly developed and manufactured in China and Germany. Emphasized productsHeartSave myPAD, which is portable and handy size The HeartSave Y/YA series, which features both of blood oxygen and blood pressure monitoring These smart devices enable remote emergency assistance and one-touch alerts, delivering efficient solutions for complex scenarios. All products are EU MDR-certified, paving the way for further expansion across the European market. PRIMEDIC Global CEO, Dr. Jack JING announced plans to increase investment in AI-powered emergency response and remote medical connectivity. PRIMEDIC will launch over 10 strategic products to enhance integrated emergency solutions spanning EMS to clinical care, creating end-to-end health solutions from prevention through emergency response to recovery. Strengthening Global Reach Through Strategic Partnership with Safe LifeWhile advancing product innovation, PRIMEDIC is also accelerating its global expansion. Financial reports show its emergency solutions segment generated ¥239 million (≈$33M USD) in 2024 revenue, a 34.05% year-on-year—driven by localized overseas operations and global supply chain partnerships. At the conference, PRIMEDIC signed a letter of intent with Safe Life Group. This expanded partnership builds on a 15-year relationship, combining shared values, complementary strengths, and integrated resources to accelerate PRIMEDIC's presence across Europe and the United States while raising public awareness for emergency preparedness and response. As emergency scenarios diversify and IoT technology advances, the AED market is rapidly evolving toward smart, accessible solutions. PRIMEDIC will leverage its technical expertise and strategic vision to accelerate product innovations and international certifications, promoting global growth and delivering next-level emergency care worldwide. View original content: SOURCE Yuwell Medical View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
26-01-2025
- Business
- Associated Press
Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell
GOLETA, Calif.--(BUSINESS WIRE)--Jan 26, 2025-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. ( 'Yuwell'), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products. The strategic collaboration is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R&D collaboration, and accelerate the entry of Inogen's brand into the Chinese market. In addition, Yuwell, through its affiliate, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% common equity interest, further cementing the collaboration and bolstering Inogen's balance sheet. 'The collaboration with Yuwell is a pivotal step in accelerating Inogen's growth trajectory. By expanding our product portfolio, global presence and enhancing our innovation pipeline, we expect to be well-positioned to capture new market opportunities,' said Kevin Smith, President and Chief Executive Officer. 'This collaboration supports our commitment to delivering long-term value to our shareholders and reinforces our vision of establishing Inogen as a platform for best-in-class respiratory solutions for patients across the globe. We are confident that our collaboration with Yuwell will play a crucial role in our continued success.' Alex Wu, Chairman of Yuwell, added, 'Inogen is a leader in the respiratory therapy market and our strategic collaboration provides both parties with the ability to broaden their geographic reach and further meet patient needs across the world. Yuwell shares Inogen's commitment to developing and providing innovative, quality products and we believe that together we can make a meaningful difference in the lives of respiratory patients. Together, Yuwell and Inogen aim to define the next generation of respiratory products.' The collaboration agreement will become effective immediately, while the purchase of the equity from Inogen is expected to close during the first quarter of 2025, subject to certain customary closing conditions. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease. For more information, please visit Inogen has used, and intends to continue to use, its Investor Relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Yuwell Since its establishment in 1998, Yuwell has been at the forefront of providing cutting-edge medical device solutions to enhance patient care and improve home healthcare worldwide. Yuwell ( generated over US $1 billion revenue in 2023, and has a broad product portfolio across respiratory treatment, diabetes management, electronic diagnostics products, first aid solutions and rehabilitation, amongst other areas. With a steadfast commitment to clinical excellence, Yuwell delivers high-quality, medically reliable products that empower healthcare professionals to achieve superior patient outcomes. With 9 state-of-the-art R&D centers and 7 advanced production facilities, Yuwell's global presence spans over 100 countries and supports more than 300,000 healthcare institutions. Yuwell touches the lives of patients around the globe by bringing professional, user-friendly medical devices into the home. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen's future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as 'aims,' 'believes,' 'anticipates,' 'plans,' 'expects,' 'will,' 'intends,' 'potential,' 'possible,' and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen's collaboration with Yuwell; satisfaction of the closing conditions under the securities purchase agreement relating to the equity investment; the timing of closing of the equity investment; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. For a detailed discussion of these and other risks that could impact Inogen's operations and financial performance, please refer to the 'Risk Factors' section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended March 31, 2024 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law. SOURCE: Inogen, Inc. Copyright Business Wire 2025. PUB: 01/26/2025 12:00 PM/DISC: 01/26/2025 12:00 PM
Yahoo
26-01-2025
- Business
- Yahoo
Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell
GOLETA, Calif., January 26, 2025--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. ( "Yuwell"), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products. The strategic collaboration is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R&D collaboration, and accelerate the entry of Inogen's brand into the Chinese market. In addition, Yuwell, through its affiliate, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% common equity interest, further cementing the collaboration and bolstering Inogen's balance sheet. "The collaboration with Yuwell is a pivotal step in accelerating Inogen's growth trajectory. By expanding our product portfolio, global presence and enhancing our innovation pipeline, we expect to be well-positioned to capture new market opportunities," said Kevin Smith, President and Chief Executive Officer. "This collaboration supports our commitment to delivering long-term value to our shareholders and reinforces our vision of establishing Inogen as a platform for best-in-class respiratory solutions for patients across the globe. We are confident that our collaboration with Yuwell will play a crucial role in our continued success." Alex Wu, Chairman of Yuwell, added, "Inogen is a leader in the respiratory therapy market and our strategic collaboration provides both parties with the ability to broaden their geographic reach and further meet patient needs across the world. Yuwell shares Inogen's commitment to developing and providing innovative, quality products and we believe that together we can make a meaningful difference in the lives of respiratory patients. Together, Yuwell and Inogen aim to define the next generation of respiratory products." The collaboration agreement will become effective immediately, while the purchase of the equity from Inogen is expected to close during the first quarter of 2025, subject to certain customary closing conditions. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease. For more information, please visit Inogen has used, and intends to continue to use, its Investor Relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Yuwell Since its establishment in 1998, Yuwell has been at the forefront of providing cutting-edge medical device solutions to enhance patient care and improve home healthcare worldwide. Yuwell ( generated over US $1 billion revenue in 2023, and has a broad product portfolio across respiratory treatment, diabetes management, electronic diagnostics products, first aid solutions and rehabilitation, amongst other areas. With a steadfast commitment to clinical excellence, Yuwell delivers high-quality, medically reliable products that empower healthcare professionals to achieve superior patient outcomes. With 9 state-of-the-art R&D centers and 7 advanced production facilities, Yuwell's global presence spans over 100 countries and supports more than 300,000 healthcare institutions. Yuwell touches the lives of patients around the globe by bringing professional, user-friendly medical devices into the home. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen's future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as "aims," "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen's collaboration with Yuwell; satisfaction of the closing conditions under the securities purchase agreement relating to the equity investment; the timing of closing of the equity investment; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. For a detailed discussion of these and other risks that could impact Inogen's operations and financial performance, please refer to the "Risk Factors" section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended March 31, 2024 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law. View source version on Contacts ir@ Sign in to access your portfolio
